Status:
COMPLETED
Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis
Lead Sponsor:
University of Campania Luigi Vanvitelli
Collaborating Sponsors:
Ceinge - Biotecnologie Avanzate s.c. a r.l.
Conditions:
Pulmonary Fibrosis
Eligibility:
All Genders
40+ years
Brief Summary
Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality ...
Eligibility Criteria
Inclusion
- Confirmed IPF diagnosis based on the 2018 ATS/ERS/JRS/ALAT guidelines \[PMID: 30168753\] or other fibrotising ILDs within the past five years,
- Age ≥ 40 years, 3) ability to provide informed consent.
Exclusion
- A current diagnosis of asthma or chronic obstructive pulmonary disease (COPD), 2) an acute PF exacerbation within the past three months.
- Use of medications who may alter metabolomic biomarkers, ex. statins.
Key Trial Info
Start Date :
May 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 18 2025
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT06974799
Start Date
May 5 2023
End Date
January 18 2025
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UOC Clinica Pneumologica L Vanvitelli
Naples, Italy, 80131